Aldose reductase — Drug Target

All drugs that target Aldose reductase — marketed and clinical-stage. Includes 2 drug classes acting on this target.

Drug classes

epalrestat · Aldose reductase inhibitor

Marketed (2)

• Eabeth · epalrestat · Metabolic
• AO-128 · Takeda · Aldose reductase inhibitor · Diabetes
  AO-128 is a selective inhibitor of aldose reductase, an enzyme in the polyol pathway that converts glucose to sorbitol.

Phase 3 pipeline (2)

• AT-007 · Applied Therapeutics, Inc. · Aldose reductase inhibitor · Endocrinology / Diabetes
  AT-007 is a small molecule that inhibits aldose reductase, the first enzyme in the polyol pathway, to reduce sorbitol accumulation and prevent diabetic complications.
• ranirestat, (AS-3201) · Sumitomo Pharma Co., Ltd. · Aldose reductase inhibitor · Endocrinology / Diabetes
  Ranirestat inhibits aldose reductase, the first enzyme in the polyol pathway, to reduce sorbitol accumulation and prevent diabetic complications.

Phase 2 pipeline (1)

• Vikasolum · Hematology
  Vikasolum works by interacting with and stabilizing vitamin K-dependent proteins in the body.